SI
CALA

Sofinnova Investments’s Calithera Biosciences, Inc CALA Stock Holding History

Sofinnova Investments’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,000
Closed -$1.96M – 78
2020
Q4 		$1.96M Buy
+20,000
New +$1.75M 0.12% 59

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments's CALA Position: Q2 2021 in Review

Sofinnova Investments sold out of Calithera Biosciences, Inc (CALA) in Q2 2021, closing a stake of 37,877 shares — an estimated $1.83M sold.

Sofinnova Investments first reported a position in CALA in Q1 2018 and held it in 10 quarters. The position peaked at $8.33M in Q4 2019. 76 funds tracked by Wall St. Rank hold CALA as of Q2 2021.

  • Sofinnova Investments reported no remaining Calithera Biosciences, Inc position as of Q2 2021 after selling out during the quarter.
  • Sofinnova Investments sold 37,877 Calithera Biosciences, Inc shares in Q2 2021, an estimated $1.83M.
  • Sofinnova Investments first reported a position in Calithera Biosciences, Inc in Q1 2018 and held it in 10 quarters.
  • Sofinnova Investments's Calithera Biosciences, Inc position peaked at $8.33M in Q4 2019.
  • 76 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2021.

Based on Sofinnova Investments's 13F filing for Q2 2021, filed 16 Aug 2021.